Business Wire·Sep 14, 2026, 4:05 PM ET

Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Yarrow Bioscience, Inc. closed its underwritten public offering of 6,634,615 common stock shares, including the full exercise of the underwriters' option to purchase an additional 865,384 shares.
The offering was priced at $26.00 per share, generating approximately $172.5 million in aggregate gross proceeds before deducting underwriting discounts, commissions, offering expenses, & advisory fees.
All securities were offered directly by Yarrow Bioscience.
The company intends to use net proceeds to fund research & development expenses for its pipeline, working capital, capital expenditures, & other general corporate purposes.
Jefferies, TD Cowen, & Guggenheim Securities served as joint book-running managers, while LifeSci Capital acted as the lead manager.
The offering was conducted under a shelf registration statement on Form S-3 declared effective by the SEC on August 19, 2026.
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing therapies for autoimmune thyroid diseases, including its lead candidate YB-101 for Graves' disease & thyroid eye disease.